Clinical trialNCT06683092RecruitingObservational

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

SponsorBoston Children's HospitalEnrollment200Cystic Fibrosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Anna Georgiopoulos, MD
Massachusetts General Hospital
Principal Investigator
clinicaltrials.gov ↗
CJ Bathgate, PhD
National Jewish Health
Principal Investigator
clinicaltrials.gov ↗
Janis Stoll, MD
Washington University at St. Louis
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Recruiting
Children'S Hospital Colorado
Aurora, Colorado, United States
Emma Lyons, PhD
Recruiting
National Jewish Health
Denver, Colorado, United States
CJ Bathgate, PhD
Recruiting
Nemours Children'S
Wilmington, Delaware, United States
David Fedele, PhDKimberly Canter, PhD
Recruiting
Nemours Children'S
Jacksonville, Florida, United States
David Fedele, PhDKimberly Canter, PhD
Recruiting
Nemours Children'S
Orlando, Florida, United States
David Fedele, PhDKimberly Canter, PhD
Recruiting
Nemours Children'S
Pensacola, Florida, United States
David Fedele, PhDKimberly Canter, PhD
Recruiting
Emory University
Atlanta, Georgia, United States
Kimberly Dickinson, MD
Recruiting
Indiana University
Bloomington, Indiana, United States
Emma Tillman, PhD PharmD
Recruiting
Kansas University Medical Center
Kansas City, Kansas, United States
Amanda Bruce, PhD
Recruiting
Johns Hopkins University
Baltimore, Maryland, United States
Noah Lechtzin, MD
Recruiting
Boston Children'S Hospital
Boston, Massachusetts, United States
Carolyn Snell, PhDMimi Stotsky, PhD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Isabel Neuringer, MD
Not, yet, recruiting
University of Michigan
Ann Arbor, Michigan, United States
Hanna Phan, PharmD
Recruiting
Washington University at St. Louis
St Louis, Missouri, United States
Andrea Coverston, MD
Not, yet, recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Traci Kazmerski, MD
Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, United States
David Finklea, MDMeghana Sathe, MD
Recruiting
Seattle Children'S Hospital
Seattle, Washington, United States
Freda Liu, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 May 2025
Primary completion: 31 Mar 2028
Completion: 30 Jun 2028
Last update posted: 3 Nov 2025
Registered enrollment: 200
Registry id: NCT06683092

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.